2Poloso N, Nagarajan S, Bumgarner GW, et al. Designer cancer vaccines made easy: protein transfer of immunostinmlatory molecules for use in therapeutic tumor vaccines[J].Front Biosci, 2001,6: D760- D775.
3Weber MC, Groger RK, Tykocinski ML. A glycosylphosphatidyhnositol -anchored cytokine can function as an artificial cellular adhesin[J]. Exp Cell Res, 1994 , 210( 1 ) :107 - 112.
4Poloso NS, Nagarajan GW, Bumgamer P, et al. Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunositimulatory molecules [ J ]. Vaccine, 2001,19(15-16) : 2 029 - 2 038.
5Nagarajan S, Selvaraj P. Glycolipid - anchored IL- 1 2 expressed on tumor cell surface induces antitumor immune response[J]. Cancer Res, 2002 , 62(10) :2 869-2 874.
8Brodbeck WG , Liu D , Sperry J , et al . localization of classical and alternative pathway regulatory activity within the decayaccelerating factor[J]. J Immunol, 1996,156(7) :2 528 - 2 533.
9McHugh RS, Ahmed SN, Wang YC, et al. Construction,purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80) [J]. Proc Nail Acad Sci USA, 1995 ,92(17) :8 059 - 8 063.
10Walter EI, Ratnoff WD, Long KE, et al. Effect of glycoinositolphosphohpid anchor lipid groups on functional properties of decay-accelerating factor protein in cells[ J].J Biol Chem, 1992 , 267(2) : 1 245 - 1 252.
